Atara Biotherapeutics, Inc.

210 articles with Atara Biotherapeutics, Inc.

• Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data

  11/4/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the upcoming first release of efficacy and safety results from its Phase 3 ALLELE study.

• Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress

  11/4/2021

  Atara Biotherapeutics, Inc. today reported financial results for the third quarter 2021, recent business highlights and key catalysts over the next several months.

• Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021

  10/28/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2021 financial results before market open on Thursday, November 4, 2021.

• Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021

  10/13/2021

  Atara Biotherapeutics, Inc. today announced new translational data based on magnetization transfer ratio (MTR) and updated Phase 1 open-label extension (OLE) clinical data in patients with progressive multiple sclerosis (MS) treated with ATA188 for up to 39 months.

• Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)

  10/4/2021

  Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel ® )

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Oct 01, 2021

  10/1/2021

  Atara Biotherapeutics, Inc. reported the grant of an aggregate of 104,386 restricted stock units of Atara’s common stock to 16 newly hired employees and stock options to purchase an aggregate of 107,813 shares of Atara’s common stock to five such newly hired employees.

• Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021

  9/29/2021

  Atara Biotherapeutics, Inc., announced the upcoming full release of new translational data and two-year open-label extension clinical data from the study of ATA188 in progressive multiple sclerosis.

• European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)

  9/27/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment to the Company’s lead product candidate, tabelecleucel (tab-cel®), for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Sep 03, 2021

  9/3/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 74,055 restricted stock units of Atara’s common stock to 16 newly hired employees and stock options to purchase an aggregate of 59,869 shares of Atara’s common stock to five such newly hired employees.

• Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference

  9/2/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a panel discussion titled, “Autologous, Allogeneic CAR-T, CAR-NK & More - Exploring the State of Play in Cell Therapy,” at the Citi 16th Annual BioPharma Virtual Conference

• Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors

  8/9/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of Ameet Mallik to the Board of Directors.

• Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress

  8/9/2021

  Atara Biotherapeutics, Inc. today reported financial results for the second quarter 2021, recent business highlights and key catalysts over the next several months.

• Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021

  8/2/2021

  Atara Biotherapeutics, Inc. today announced the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021.

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2021

  8/2/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 110,626 restricted stock units of Atara’s common stock to 28 newly hired employees and stock options to purchase an aggregate of 69,744 shares of Atara’s common stock to 8 such newly hired employees.

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - July 02, 2021

  7/2/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 124,580 restricted stock units of Atara’s common stock to 35 newly hired employees and stock options to purchase an aggregate of 99,585 shares of Atara’s common stock to 12 such newly hired employees.

• Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers

  7/1/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the Company has joined the Rare Disease Company Coalition.

• Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

  6/7/2021

  Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced a combined long-term overall survival (OS) analysis from three clinical studies of tabelecleucel

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - June 04, 2021

  6/4/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 140,861 restricted stock units of Atara’s common stock to 28 newly hired employees and stock options to purchase an aggregate of 124,966 shares of Atara’s common stock to 7 such newly hired employees.

• Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - May 14, 2021

  5/14/2021

  Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported the grant of inducement awards to Cokey Nguyen, its Senior Vice President, Chief Scientific Officer.

• 

  BioSpace Movers & Shakers, May 14

  5/14/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.